CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Canadian Cancer Trials Group
Northside Hospital, Inc.
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Shanghai Jiao Tong University School of Medicine
National Cancer Institute (NCI)
University of Washington
Thomas Jefferson University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Yale University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Genmab
Henan Cancer Hospital
University of Washington
University College, London
Alliance for Clinical Trials in Oncology
Masonic Cancer Center, University of Minnesota
Hackensack Meridian Health
Alliance for Clinical Trials in Oncology
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Dana-Farber Cancer Institute
Canadian Cancer Trials Group
St. Jude Children's Research Hospital
The First Hospital of Jilin University
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Gilead Sciences
Center for International Blood and Marrow Transplant Research
Allogene Therapeutics
City of Hope Medical Center
University of Washington
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Incyte Corporation
M.D. Anderson Cancer Center
University of Miami
Gilead Sciences
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Baptist Health South Florida
Malaghan Institute of Medical Research
Allogene Therapeutics
Fred Hutchinson Cancer Center
Jonsson Comprehensive Cancer Center
St. Jude Children's Research Hospital